A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.

[1]  W. Schaffner,et al.  1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States , 2020 .

[2]  J. Sanz,et al.  Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Cohen,et al.  Invasive Disease Potential of Pneumococcal Serotypes in Children After PCV13 Implementation. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Charles Y. Tan,et al.  Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional Streptococcus pneumoniae Serotype–specific Polysaccharides in Human Urine , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Regueira,et al.  Distribution of PCV13 and PPSV23 Streptococcus pneumoniae serotypes in Argentinean adults with invasive disease, 2013-2017. , 2020, Revista Argentina de microbiologia.

[6]  Miwako Kobayashi,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.

[7]  M. P. van der Linden,et al.  Limited indirect effects of an infant pneumococcal vaccination program in an aging population , 2019, PloS one.

[8]  T. Wiemken,et al.  Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. , 2019, Vaccine.

[9]  D. Swerdlow,et al.  Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States , 2019, Human vaccines & immunotherapeutics.

[10]  F. Avci,et al.  Invasive pneumococcal disease in relation to vaccine type serotypes , 2019, Human vaccines & immunotherapeutics.

[11]  A. Gurtman,et al.  Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults , 2019, Human vaccines & immunotherapeutics.

[12]  P. Spreeuwenberg,et al.  Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries , 2018, BMC Infectious Diseases.

[13]  William A. Mattingly,et al.  Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Grobbee,et al.  Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  H. Nair,et al.  Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis , 2017, PloS one.

[16]  Jérémie F. Cohen,et al.  Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries , 2017, Expert review of vaccines.

[17]  Yadong Cui,et al.  Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world , 2017, Human vaccines & immunotherapeutics.

[18]  E. Emini,et al.  Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. , 2016, Vaccine.

[19]  W. Schaffner,et al.  Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Noele P. Nelson,et al.  Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. , 2016, Morbidity and mortality weekly report. Surveillance summaries.

[21]  R. Cohen,et al.  The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014 , 2016, Human vaccines & immunotherapeutics.

[22]  W. Hanage,et al.  Interim results of an ecological experiment — Conjugate vaccination against the pneumococcus and serotype replacement , 2016, Human vaccines & immunotherapeutics.

[23]  C. Whitney,et al.  Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  T. Pilishvili,et al.  Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines. , 2015, Vaccine.

[25]  W. Self,et al.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. , 2015, The New England journal of medicine.

[26]  E. Emini,et al.  Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. , 2015, The Journal of infectious diseases.

[27]  M. P. van der Linden,et al.  Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany , 2015, PloS one.

[28]  M. Nahm,et al.  Pneumococcal Capsules and Their Types: Past, Present, and Future , 2015, Clinical Microbiology Reviews.

[29]  D. Grobbee,et al.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. , 2015, The New England journal of medicine.

[30]  W. Schaffner,et al.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. , 2015, The Lancet. Infectious diseases.

[31]  P. Castiglia,et al.  Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western Europe , 2014, Advances in Therapy.

[32]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.

[33]  G. Rohde,et al.  Pneumococcal infection in adults: burden of disease. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  E. Emini,et al.  Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. , 2014, Vaccine.

[35]  E. Emini,et al.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. , 2013, Vaccine.

[36]  E. Emini,et al.  Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. , 2013, Vaccine.

[37]  K. O'Brien,et al.  Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques , 2013, PloS one.

[38]  C. Whitney,et al.  Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.

[39]  D. Mant,et al.  Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells , 2012, The Journal of infectious diseases.

[40]  Pneumococcal vaccines WHO position paper--2012. , 2012, Releve epidemiologique hebdomadaire.

[41]  D. Levy-bruhl,et al.  Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[42]  Update: pneumococcal polysaccharide vaccine usage--United States. , 1984, MMWR. Morbidity and mortality weekly report.